Medication info

Sambika Tablet 5/40 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Samsung Pharmaceutical Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Expired

MFDS item code 201902833 · Approved 2019.05.02

This product's status changed to Expired on 2024.05.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal insufficiency (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal insufficiency. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this medicine, under Precautions for Use.) ∘Elderly patients: Generally, start treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbidities into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Samsung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Amlodipine or Olmesartan Medoxomil monotherapy is recommended for patients with essential hypertension. These medications effectively lower blood pressure and help when blood pressure control is not optimal. By maintaining stable blood pressure, the risk of cardiovascular diseases is reduced. Continuous use plays an important role in preventing complications. These drugs assist patients in managing their blood pressure and improving health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal insufficiency (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal insufficiency. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this medicine, under Precautions for Use.) ∘Elderly patients: Generally, start treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbidities into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm or death to the fetus and newborn if administered to pregnant women during the second and third trimesters. Therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to any of the components of this medication or similar drugs, pregnant or nursing women, patients with severe hepatic impairment or aortic stenosis, patients with bile duct obstruction, kidney dialysis patients, patients in shock, specific diabetic patients, and patients with severely impaired kidney function should not take this medication. Patients with dehydration or salt depletion may experience hypotension, therefore their condition should be closely monitored at the start of treatment, and appropriate interventions should be taken if hypotension occurs. Due to the vasodilation effect, some patients may experience acute hypotension, so caution is required, especially for patients with heart valve issues. Use of this medication in patients with severe obstructive coronary artery disease or congestive heart failure should be approached with caution, and their heart condition should be closely monitored. For patients with reduced kidney function, this medication may affect kidney function, so regular monitoring of kidney function is essential. In patients with impaired liver function, the metabolism of this medication may slow down, requiring caution during use. Side effects such as dizziness, headache, hypotension, orthostatic hypotension, drowsiness, nausea, vomiting, diarrhea, rash, swelling, and others may occur; if any unusual symptoms occur, patients should consult a healthcare professional immediately. During pregnancy, there may be risks to the fetus, thus this medication should not be used if pregnant or planning to become pregnant, and an alternative safe medication should be sought if necessary. Nursing women should be aware that this medication may transfer to breast milk, potentially causing adverse reactions in the infant; thus, breastfeeding should be stopped or medication use should be discontinued. The safety and efficacy of this medication have not been established in children under 18 years old, and it is not recommended. Elderly patients should have their dosage adjusted carefully considering reduced kidney and liver function, and attention should be paid to the possibility of side effects. In case of overdose, severe hypotension, vascular dilation, and tachycardia may occur, requiring immediate medical attention and close monitoring of blood pressure and heart function. This medication should be stored in a tightly closed container to avoid moisture and heat, and kept out of the reach of children. There may be possible interactions with other medications during treatment with this drug, so patients should inform their healthcare provider of any other medications they are taking, particularly avoiding concomitant use with grapefruit juice.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory loss
  • syncope
Show 82 more
  • vertigo
  • palpitations
  • tachycardia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • frequent urination
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • weakness
  • facial swelling
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening of cerebral infarction
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • non-cardiogenic pulmonary edema
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering. It is recommended to maintain storage temperatures between 1 degree and 30 degrees Celsius to safely preserve its efficacy.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.